Table 2.
All patients N = 148 |
PH (−) N = 83 |
PH (+) N = 65 |
P value | |
---|---|---|---|---|
General anesthesia | 98 (69.5) | 53 (67.1) | 45 (72.6) | 0.48 |
Access type, n (%) | 0.83 | |||
Transfemoral | 117 (79.1) | 66 (79.5) | 51 (78.5) | |
Transapical | 28 (18.9) | 16 (19.3) | 12 (18.5) | |
Transaortic | 2 (1.4) | 1 (1.2) | 1 (1.5) | |
Subclavian | 1 (0.7) | 0 (0.0) | 1 (1.5) | |
Device implanted, n (%) | 0.41 | |||
Corevalve/Evolut R, n (%) | 29 (19.6) | 18 (21.7) | 11 (16.9) | |
Edwards Sapien | 95 (64.2) | 48 (57.8) | 47 (72.3) | |
Jena | 10 (6.8) | 7 (8.4) | 3 (4.6) | |
Lotus | 9 (6.1) | 7 (8.4) | 2 (3.1) | |
NVT | 5 (3.4) | 3 (3.6) | 2 (3.1) | |
Prosthesis size, n (%) (mm) | 0.82 | |||
23 | 30 (20.3) | 18 (21.7) | 12 (18.5) | |
25 | 8 (5.4) | 5 (6.0) | 3 (4.6) | |
26 | 56 (37.8) | 29 (34.9) | 27 (41.5) | |
27 | 8 (5.4) | 5 (6.0) | 3 (4.6) | |
29 | 38 (25.7) | 23 (27.7) | 15 (23.1) | |
31 | 8 (5.4) | 3 (3.6) | 5 (7.7) | |
Prosthesis size, median (IQR) (mm) | 26.0 (25.0–29.0) | 26.0 (25.0–29.0) | 26.0 (26.0–29.0) | 0.74 |
TG max after TAVI, median (IQR) (mmHg) | 13.0 (10.0–19.0) | 12.8 (10.0–19.0) | 15.0 (10.1–19.0) | 0.21 |
TG mean after TAVI, median (IQR) (mmHg) | 7.4 (5.1–10.0) | 7.0 (5.0–10.5) | 8.0 (6.0–10.0) | 0.29 |
LVEF after, median (IQR) (%) | 48.0 (41.0–55.0) | 47.0 (40.0–50.0) | 50.0 (45.0–60.0) | 0.15 |
AR after, n (%) | 0.041 | |||
0 | 84 (56.8) | 45 (54.2) | 39 (60.0) | |
1 | 55 (37.2) | 35 (42.2) | 20 (30.8) | |
2 | 7 (4.7) | 1 (1.2) | 6 (9.2) | |
3 | 2 (1.4) | 2 (2.4) | 0 (0.0) | |
Radiation dose, median (IQR) (mGy) | 721.0 (632.5–827.5) | 721.0 (634.0–826.0) | 721.0 (631.0–823.0) | 0.83 |
Contrast medium load, median (IQR) (ml) | 75.0 (50.0–137.5) | 75.0 (50.0–100.0) | 75.0 (75.0–150.0) | 0.07 |
Fluoroscopy time, median (IQR) (min) | 13.0 (12.0–15.0) | 13.0 (11.5–15.0) | 13.0 (12.0–14.0) | 0.62 |
AR aortic regurgitation, LVEF left ventricle ejection fraction, TG transaortic gradient